Fig. 1
From: Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
Trial design. Baseline immune status of each group and expected outcome after DENV3 vaccination (A). The trial includes optional pre-vaccination consent, blood draw, and lymph node aspiration, which can occur between days − 59 and 0 (B). Vaccination and subsequent blood draws, viremia assessments, and lymph node aspirations are outlined. Created with BioRender.com.